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Abstract
Background: Tuberculosis (TB) is a major health problem and HIV is the major cause of the 
increase in TB. Sub-Saharan Africa is endemic for both TB and HIV infection. Determination of the 
prevalence of M. tuberculosis strains and their drug susceptibility is important for TB control.
TB positive culture, BAL fluid or sputum samples from l3 0  patients were collected and genotyped. 
The spoligotypes were correlated with anti-tuberculous drug susceptibility in HIV-infected and 
non-HIV patients from Tanzania.
Results: One-third of patients were TB/HIV co-infected. Forty-seven spoligotypes were identified.
Fourteen isolates (l0.8%) had new and unique spoligotypes while l l6  isolates (89.2%) belonged to 
33 known spoligotypes. The major spoligotypes contained nine clusters: CASl-Kili 30.0%, L A M ll- 
ZWE 14.6%, ND 9.2%, EAI 6.2%, Beijing 5.4%, T-undefined 4.6%, CASl-Delhi 3.8%, T l 3.8% and 
LAM9 3.8%. Twelve (l0.8%) of the l l l  phenotypically tested strains were resistant to  anti-TB 
drugs. Eight (7.2%) were monoresistant strains: 7 to  isoniazid (INH) and one to streptomycin. Four 
strains (3.5%) were resistant to  multiple drugs: one (0.9%) was resistant to  INH and streptomycin 
and the other three (2.7%) were MDR strains: one was resistant to INH, rifampicin and ethambutol 
and two were resistant to  all four anti-TB drugs. Mutation in the katG  gene codon 3 15 and the rpoB 
hotspot region showed a low and high sensitivity, respectively, as predictor of phenotypic drug 
resistance.
Conclusion: CASl-Kili and LA M ll-ZW E  were the most common families. Strains of the Beijing 
family and CASl-Kili were not o r least often associated with resistance, respectively. HIV status 
was not associated with spoligotypes, resistance or previous TB treatment.
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Background
Tuberculosis (TB) persists as a major cause of morbidity 
and mortality, affecting almost a third of the world's pop­
ulation [1]. Inadequate detection and cure rates have been 
identified as reasons for a m ounting global tuberculosis 
burden [2]. Human immunodeficiency virus (HIV) is by 
far the major cause of the current increase in tuberculosis 
infection. The presence of HIV increases the risk of reacti­
vation of a latent Mycobacterium tuberculosis (MTB) infec­
tion [3] and rapid thus progression of the infection [4]; 
HIV also increases MTB transmission rates at the commu­
nity level, therefore threatening the health and survival of 
HIV- seronegative individuals as well [5]. Sub-Saharan 
Africa is endemic for both TB and HIV infection [6], and 
pulmonary tuberculosis (PTB) in  the HIV-affected coun­
tries of eastern and southern Africa, such as Tanzania, has 
increased rapidly in the past decades [7].
Molecular genotyping is an im portant tool for the under­
standing of TB epidemiology. It can predict transmission 
rate and identify dom inant strains, strains with an 
enhanced capacity to spread, strains associated with out­
break [8], severe disease [9] and drug resistance. Spacer 
oligonucleotide typing (spoligotyping) is one of the 
molecular genotyping techniques; it is fast, robust, relia­
ble, easy to perform, and cost-effective [10]. On the basis 
of the variability of the direct-repeat (DR) locus [10,11], 
spoligotyping can detect different M. tuberculosis strains, 
such as the Beijing genotype which is associated with 
enhanced febrile response in patients during treatment, 
and multiple drug resistance (MDR) [9,12,13].
For TB control, monitoring the emergence of drug resist­
ant strains is essential. While detection of drug resistance 
by phenotype is hindered by the prolonged time to iden­
tify resistant strains, genotypic prediction of drug resist­
ance is faster. Data are accumulating on the correlation 
between gene mutations and phenotypic resistance. Such 
data however are sparse, particularly from sub-Saharan 
Africa where the disease burden is highest. The primary 
mechanism for acquiring resistance in M. tuberculosis is 
the accumulation of point mutations in gene coding for 
drug targets or drug-converting enzymes [14]. Mutations 
in the catalase peroxidase gene (katG) [15,16] and in a 
gene encoding the enoyl acyl carrier protein reductase 
(inhA) [17] have been found to account for 60 to 70% and
10 to 15% of INH-resistant MTB isolates, respectively 
[18]. Mutations resulting in an amino acid change within 
the 81-bp core region of the RNA polymerase P-subunit 
(rpoB) gene are found in 96% of rifampicin-resistant M. 
tuberculosis strains [19].
The objectives of this study were to determine the genetic 
biodiversity of MTB by spoligotyping and to correlate spo­
ligotypes and anti-tuberculous drug susceptibility in HIV-
infected and non-HIV patients in northern Tanzania, one 
of the TB and HIV endemic countries of eastern Africa.
Results
Characteristics o f  the study population
In total 130 positive-culture samples from 220 patients 
were included in the study. The majority of the patients in 
this study were from the Chagga and Masai tribes, 41.1% 
and 11.6%, respectively. Other tribes were represented by 
less than 5% each. Fifty-four (41.9%) were peasants, 28 
(21.7%) business people, 18 (14%) miners and 10 
(7.8%) herders, the remaining had other occupations. The 
m ean age (SEM) was 37 years (1). Eighty-three (63.8%) 
were male patients. Fourteen patients (10.8%) had a his­
tory of previous treatment for tuberculosis. Forty-seven 
(36.2%) patients were HIV seropositive. Mean CD4 cell 
count (SEM) for the HIV seropositive patients was 200 
(35) cells/ml and for the HIV seronegative group the 
mean CD4 count (SEM) was 555 (38) cells/ml.
Spoligotypes
A total of 47 spoligotypes was identified among the 130 
M. tuberculosis isolates. Fourteen isolates (10.8%) had new 
and unique spoligotypes (SIT 0) while 116 isolates 
(89.2%) belonged to 33 previously known spoligotypes. 
A total of 106 isolates (81.5%) from nine different phylo­
genetic clusters formed the major isolates (i.e. with five or 
more isolates for each spoligotype). These were CAS1-Kili 
with 39 (30%) isolates (strains 60-98), LAM11- ZWE 19 
(14.6%) (strains 0-19), ND 12 (9.2%)(strains 119-130), 
EAI 8 (6.2%)(strains 47-54), Beijing 7 (5.4%)(strains 
109-115) and T-undefined 6 (4.6%) (strains 41-46) as 
well as CAS1-Delhi (strains 99-103), T1 (strains 31-35) 
and LAM9 (strains 20-24) with 5 isolates (3.8%) each 
(Figure 1).
Three new shared spoligotypes (a common pattern shared 
by two or more isolates) were established from our find­
ings by comparing them with the spoligotypes which were 
available in the SpolDB4: one EAI (SIT 2482, strain 49) 
with that found in Zambia, one T-undefined (SIT 2482, or 
SIT 2484, strain 42) with that found in the USA and one 
CAS1 variant -  undefined (SIT 2485, strain 107) with that 
found in Sweden.
D rug  susceptibility testing (DST )
O ut of 111 TB isolates which were subjected to DST, 12 
(10.8%) were resistant to at least one anti-TB drug. Eight 
of the 111 (7.2%) were monoresistant strains: 7 resistant 
to INH and one to streptomycin. Four strains (3.5%) were 
resistant to multiple drugs: one (0.9%) was resistant to 
INH and streptomycin and the other three (2.7%) strains 
were MDR strains: two (1.8%) strains were resistant to all 
four anti-TB drugs and one (0.9%) strain was resistant to 
INH, rifampicin and ethambutol Resistance of the 111
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Spoligotyping patterns
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Figure 1
Description of Mycobacterium tuberculosis strains and clusters (SIT) found in Tanzania. DST = Drug Susceptibility Testing. SIT = 
spoligo-international type. W T  = wild type. MT = mutant type.
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isolates for each drug was as follows: INH 11 strains 
(9.9%), streptomycin 4 (3.6%), rifampicin 3 (2.7%), and 
ethambutol 3 (2.7%).
Four of the 130 MTB isolates (3.1%) were found to have a 
m utation in a katG gene codon 315. Four of the 22 tested 
isolates were found to have a m utation in the hotspot 
region of the rpoB gene. Of the 11 strains phenotypically 
resistant to INH, four strains were also genotypically 
resistant to INH. The sensitivity of the m utant katG gene 
to predict phenotypical resistance to INH was 30.8% and 
the specificity was 100%.
All three strains phenotypically resistant to rifampicin 
were also genotypically resistant to rifampicin. Both sen­
sitivity and specificity of a m utation in the rpoB gene to 
predict phenotypical resistance to rifampicin was 100%.
As shown in Table 1, two of the 49 isolates (4.1%) belong­
ing to four variants of the CAS1 family (CAS1-Kili, CAS2, 
CAS 1-undefined, CAS1-Delhi) showed resistance to at 
least one drug and four could not be tested. Six of the 30 
isolates (20%) of the LAM family (LAM3 or S, LAM9, 
LAM11-ZWE) showed resistance to one or more anti-TB 
drugs. Three of the 16 isolates (18.8%) of the T family (T3- 
UGA, T1, T-undefined) showed resistance. One of the 13 
isolates (7.7%) of the EAI family (EAI, EAI-variant, EAI- 
undefined), one of the 12 isolates (8.3%) of the ND fam­
ily, and one of the three isolates (33.3%) from the MANU 
family (MANU1, MANU2) showed resistance to at least 
one anti-TB drug. None of the seven M. tuberculosis Beijing 
isolates was resistant to anti-TB drugs.
Out of the 12 resistant isolates two (14.3%) were new and 
unique isolates (strain 116 and 126): the three MDR iso­
lates were CAS1- Kili (strain 89), EAI (strain 48) and LAM 
11 -  ZWE (strain 13) (Figure 1)
Previous TB treatment, H IV  status and drug resistance
O ut of 14 patients who had a history of previous treat­
m ent for PTB, one (7.1%) had a MDR-MTB strain and the 
other 13 (92.9%) had strains sensitive to all four first line 
anti-TB drugs. Five of the 47 HIV-infected individuals 
(10.6%) showed resistance to at least one drug. Three of 
the 47 HIV -  infected individuals (6.4%) had a history of 
previous treatment for TB and none of them had strain 
resistant to anti-TB drug.
Discussion
There was a wide diversity of spoligotypes in this study 
group; the 130 MTB isolates produced 47 different spoli- 
gotypes. The clades observed in this study were more than 
three-quarters of the total of 62 clades/lineages currently 
documented in the fourth international spoligotyping 
database, SpolDB4 [20]. This diversity may be attributed 
to increased hum an movement in this area due tourism, 
mining, asylum seeking (refugees) and transborder/inter­
national business. Historically, many people from Europe 
and Asia also lived here during pre- and post-independ­
ence times. The structure of the TB population is deter­
m ined by geography, demography, and hum an 
migration. Studies have shown that the host's geographi­
cal origin is predictive of the clinical M. tuberculosis iso­
lates and there is an apparent stable association of TB 
bacilli populations with their hum an hosts in various 
environments [21]. New types (i.e. orphan spoligotypes) 
accounted for one-tenth of all spoligotypes in this study. 
The low percentage of new types may also be a result of 
increased hum an movements. Countries with a history of 
isolation have been shown to have a large number of new 
spoligotypes [8]. In this study two of the three new shared
Table 1: Distribution of seven of the phylogenetic families by age, smear results, H IV  status, CD4 count (n = 130) and phenotypic 
resistance for a TB drug (n = 111)
Family Isolates 
N = I30 N
Age 
= I30
Smear positive 
N = I30
HIV positive 
N = I30
CD4cell/ml 
N = I30
Resistant 
N = I I I
% n/N mean SEM % n/N % n/N mean SEM % n/N
CAS * 37.7 49/I30 38 2 8I.6 40/49 34.7 I7/49 47I 64 4.4 2/45
LAM ** 23.2 30/I30 39 3 83.3 25/30 26.7 8/30 437 55 I8.5 5/27
T *** I2.3 I6/I30 35 2 8I.3 I3 /I6 50.0 8/I6 436 92 I4.3 2 /I4
EAI # I0.0 I3/I30 39 3 69.2 9/I3 46.2 6/I3 432 64 8.3 I/I2
ND 9.2 I2/I30 37 4 58.3 7/I2 4I.7 5/I2 4I3 99 I6.7 I/6
Beijing 5.4 7/I30 29 2 85.7 6/7 I4.3 I/7 380 69 0.0 0/6
MANU ## 2.3 3/I30 32 4 I00 3/3 66.7 2/3 I95 I4I I00 I/I
*  CAS: CASI-Kili; CASI-Delhi; CASI-undefined;CAS2
**  LAM: LAM II-ZW E; LAM9; LAM3 o r S; LAM-undefined 
** *  T: T-undefined; T I; T3-UGA; T3
#  EAI: EAI; EAI-variant; EAI-undefined 
# #  MANU: M AN U I; MANU2.
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spoligotypes were formed between two geographically 
widely separated isolates (strain 42 and 107). This again 
is more likely to be due to the increased hum an move­
m ent than homoplasy (i.e. acquisition of two similar 
structures without a common ancestor). If it is assumed 
that tuberculosis may have affected the early hominids in 
East Africa, evolved clonally and then spread to the rest of 
the world coincidentally with hum an migration out of 
Africa [13-16], then it is interesting to find that almost all 
strains go back to the origin of Homo sapiens sapiens. The 
site of this study is within the area of Olduvai Gorge in 
northern Tanzania, which is regarded as the "cradle of 
mankind". In this context, strains no. 116-118 with 
MANU-derived spoligotypes are of particular interest (Fig­
ure 1).
Among the different phylogenetic clusters found in this 
study, there were only nine major clusters with five or 
more isolates, bu t they comprised 81.5% of all isolates. 
This indicates the high transmission rate within the popu­
lation. This high transmission rate may also be influenced 
by the marked prevalence of HIV infection which 
increases the risk of tuberculosis for all people in a com­
munity, both those with HIV infection and the HIV seron­
egative community members [5]. Two clusters were by far 
the m ost prevalent: CAS1-Kili and LAM11-ZWE family, 
with a prevalence exceeding ten percent. The predomi­
nance of these two families by more than ten percent has 
been demonstrated by another study based on IS 6110- 
restriction fragment length polymorphism (RFLP). The 
study showed that the Kilimanjaro and Meru families 
were the most prevalent in this area [22], the names of the 
families being derived from the two adjacent mountains 
found in this area. While the Kilimanjaro family refers to 
CAS1-Kili, the Meru family is identical to LAM11-ZWE 
[20]. Another recent study, performed in Dar-es-Salaam, 
suggested the existence of new CAS1-Kili genotype vari­
ants (designated as CAS1-Dar) [23]. However, the absence 
of spacer 2 and 15 in the spoligotype-signatures reported 
by these authors was no t found, even once, in our study. 
A single clinical isolate, strain 104 (ST247) looks similar 
to the CAS-Dar variants. This may be explained either by 
a specific loss of spacers 2 and 15 in the CAS1-Dar variants 
or by false negative hybridization spots. Spacer 2 and 15 
may indeed sometimes provide barely interpretable 
results. If confirmed, the absence of spacers 2 and 15 may 
provide interesting clues about the microevolution of 
CAS1-Kili in Tanzania.
More than 5% of cases were Beijing isolates which were 
the fifth most frequent spoligotype. The presence of seven 
Beijing isolates had already been reported in Dar-es- 
Salaam [23]. The mean age of the patients with the Beijing 
family was the lowest compared to those with other iso­
lates (Table 1). It has already been reported that Beijing is
associated with young age [24] which implies recent and 
ongoing transmission.
A striking finding was that not one single case of M. bovis 
or M. africanum was found in this study. This study cohort 
consisted mainly of peasants and herders, including the 
Masai people who are essentially semi-nomads or herders 
and their staple food includes milk and meat. In Uganda 
which is a neighbouring country, other genotypes of the 
M. tuberculosis complex, previously designated as "M. afri­
canum 2" are the major cause of hum an tuberculosis [25]. 
This finding may be a result of improved livestock and 
animal husbandry in  Tanzania or due to anthropologi­
cally rooted differences between Uganda and Tanzania.
All resistant isolates except one were resistant to INH, 
either alone or in combination with other drugs. The level 
of INH resistance was high; a similar trend has been 
observed in many African countries; in some countries up 
to one-third of the isolates is resistant to INH [26-29]. 
This rate is alarming, especially since INH is the first-line 
drug which is used throughout the course of TB treatment. 
This also means a high probability of the development of 
MDR in the future, since it has been observed that MDR 
often develops from initial INH-monoresistant strains 
[28]. Several reports show a low prevalence of MDR-MTB 
in Africa compared to Asia and Eastern Europe [30]. But 
the trend seems to be steadily increasing since previous 
reports from Tanzania showed that INH monoresistance 
was about 5% and MDR was about 1% [31] while our 
study reveals a more than two-fold increase in both INH 
resistance and MDR. The upward trend in resistance has 
also been noted in neighboring countries [30,32].
Despite its high prevalence, the CAS 1 family showed the 
least association with anti-TB drug resistance (Table 1); 
family LAM and T were more frequently associated with 
anti-TB drug resistance.
Another interesting aspect was the fact that all MTB Bei­
jing isolates in this study were susceptible to all anti-TB 
drugs unlike reports from other studies [28,33]. A previ­
ous study in Indonesia also showed no significant associ­
ation between Beijing strains and drug resistance [9].
One-third of the study population was infected by both 
HIV and TB; this is the common trend in sub Saharan 
Africa [34]. The association of HIV infection, however, 
with previous treatment for TB was not statistically signif­
icant and that with anti-TB drug resistance was absent in 
this study. The smaller number of HIV- infected patients 
with a history of previous treatment for TB may be attrib­
uted to high mortality associated with the first MTB infec­
tion in TB/HIV co-infected patients [35,36]. There was no 
association between HIV status and spoligopatterns
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except for Beijing whereby only one person was HIV sero­
positive.
The mean CD4 count for patients with Beijing was the 
lowest, although all patients except one were HIV seron­
egative. This low CD4 count despite being HIV seronega­
tive may be due to the pronounced virulence of the 
Beijing strain. It has been demonstrated that the Beijing 
family is more virulent than other M. tuberculosis strains. 
The virulence is attributed to the ability of the strain to 
produce phenolic glycolipid which is able to interfere 
with host immunity [37].
Conclusion
In this study we found a wide diversity of spoligotypes 
with predominance of two genotype families. The Beijing 
family was also among the prevalent phylogenetic cluster. 
The most prevalent cluster CAS1-Kili and the most viru­
lent Beijing were not or barely associated with anti-TB 
drug resistance.
A substantial proportion of resistant isolates was found, 
INH monoresistance being the highest and thus signaling 
the danger of increasing MDR in the future. MDR was 
higher than that described in previous reports from Tan­
zania.
Methods
In the Kilimanjaro region of northern Tanzania, between 
April and September 2005, we collected sputum or bron- 
choalveolar lavage (BAL) fluid by direct expectoration or 
bronchoscopy, respectively, from 220 patients suspected 
of having PTB. The patients presented with coughing, 
evening fevers and abnormal chest x-rays. The patients 
were seen at Kibong'oto National Tuberculosis Referral 
Hospital (KNTH) and Kilimanjaro Christian Medical cen­
tre (KCMC), a tertiary care hospital. The specimens were 
obtained prior to initiation of TB treatment. For each 
patient, any history of TB treatment in the past was noted. 
Specimens were digested and decontaminated with NaLC 
and 2%NaOH by the standard procedure [38]. Sediments 
were used for diagnosis of TB: direct smears for acid-fast 
bacilli (AFB) by the Ziehl-Neelsen (ZN) m ethod [38] and 
cultures in Lowenstein-Jensen (LJ) solid medium in three 
slants with or without 0.75% glycerol or with 0.6% 
sodium pyruvate. One hundred and thirty TB-positive cul­
ture samples (confirmed by smear) were subjected to spo- 
ligotyping and genotypic testing for drug resistance to 
isoniazid (INH) and 22 for rifampicin; 111 samples 
underwent phenotypic DST because the reculture of nine­
teen strains was no t possible. Phenotypic drug resistance 
testing was performed for INH, rifampicin, ethambutol, 
and streptomycin and genotypic testing was carried out 
for a m utation in the katG 315 codon to INH and for a 
m utation in the rpoB hotspot region to rifampicin. Geno­
typic resistance to rifampicin was tested with samples 
which were INH-resistant, contained phenotypic 
rifampicin-resistant strains, or had selected spoligotypes; 
phenotypic rifampicin -sensitive strains were used as con­
trols.
D N A  extraction
A loopful of Mycobacterial colonies from cultures was sus­
pended in 1 ml of physiological saline solution and 
heated at 80 °C for 10 minutes to kill the bacilli. The 
supernatant obtained was stored at -20°C.
Spoligotyping
Amplification of the spacers was performed using DNA 
extract and primers (DRa and DRb) corresponding to the 
direct repeat (DR) region of the genome of M. tuberculosis 
according to the procedure described by v.d. Zanden et al 
[39]. Briefly, 10 |il of the DNA extract were mixed with 40 
|il PCR mix containing 5 |il 10x PCR buffer, 3 |il magne­
sium chloride (25 mM), 4 |il dNTP mix (2.5 mM dNTP 
each), 50 pmol DRa primer, 50 pmol DRb primer, 0.2 |il 
Taq polymerase and 0.25 |il Tris 1 M (pH 9.0), 0.5 |il UDG 
(1 U/|il). Amplification and hybridization were per­
formed according to the manufacturer's manual (Isogen 
Bioscience BV, Maarssen, The Netherlands). The hybrid­
ized membrane was exposed to X-ray film for detection of 
the hybridization signal. The X-ray film (Hyperfilm™ ECL, 
Amersham Bioscience UK Ltd.) was read manually to 
obtain a complete pattern of the spacers between the DR 
regions harbored by a particular strain. Preventive meas­
ures were taken against contamination with either previ­
ously amplified DNA or amplicons from previous 
reactions; the procedure was described by Kwok et al. and 
Longo et al; respectively [40,41]. Computer-assisted anal­
ysis of spoligotyping patterns was carried out with Bionu­
merics 4.0 (Applied Maths, St-Martin-Latem, Belgium).
The patterns obtained received a spoligo-international 
type (SIT) according to the cluster assignment after the 
sequences were processed with the International Spoligo- 
type Database of the Institut Pasteur de Guadeloupe 
[20,42]. New spoligotypes identified in the study were 
added to the SpolDB4.
Phenotypic drug resistance testing
The proportional method for drug susceptibility testing 
(DST) of M. tuberculosis, as described in the manual, was 
used [43]; Briefly, for each drug a 1: 10 dilution of stand­
ardized inoculum was inoculated onto the control and 
drug-containing media. The extent of growth in the 
absence or presence of drug was compared and expressed 
as a percentage. If growth at the critical concentration of a 
drug was >1%, the isolate was considered to be clinically 
resistant. 7H10 agar with 0.2 and 1 mg/l isoniazid (INH),
1 en 5 mg/l rifampicin, 5 and 10 mg/l ethambutol and 5
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and 10 mg/l streptomycin were used 7H10 agar tubes with
I ml of culture in 9 ml sterile aquadest served as control.
Genotypic IN H  and rifampicin resistance testing
Amplification of katG gene containing codon 315 was 
performed for detection of INH resistance, using a set of 
primers; Foward (GGG CTT GGG CTG GAA GAG) and 
Reverse (ACA ACA GTT TCC TCG AGA TCC TGT). This 
resulted in a 122 bp long product. Detection of the katG- 
315 wildtype took place by a FAM-labeled probe (5' 
CGCGATCACCAGCGGCATCG 3') and detection of the 
most common katG-315 m utation from AGC to ACC by a 
VIC-labeled probe (5'CGC GAT CAC CAC CGG CAT CG 
3'). DNA amplification/detection was performed in 30 |il 
reaction volume with the ABI Prism® 7000 Sequence 
Detection System (Applied Biosystems): template DNA, 
400 nM of each primer and 200 nM of each probe. The 
PCR-program consisted of 2 m in at 50°C, 10 m in at 
95°C, 45 cycles of 15 seconds at 95°C, 1 m in at 60°C.
For the detection of rifampicin resistance, sequencing was 
carried out with the 3100-Avant sequencer (Applied Bio­
systems). Amplification of a 437 bp fragment, containing 
the rpoB-hotspot region, took place with a PTC 200 ther­
mocycler (Biozym) by forward primer rpoB-F1 and reverse 
primer rpoB-R1, as described by v.d. Zanden et al. [19]. 
The sequence reaction was performed with approximately 
50 ng DNA. The results of sequencing were compared to 
the rpoB-hotspot wildtype using Bionumerics software 
(Applied Maths, St-Martin-Latem, Belgium).
Blood was collected from all patients for detection of anti­
HIV antibodies using the Capillus™ HIV-1/HIV-2 rapid 
test (Trinity Biotech, Bray, Ireland) according to the m an­
ufacturers instructions, with positive and negative con­
trols for each test run. Samples positive in the rapid test 
were confirmed by ELISA using Vironostika® HIV uniform
II ag/ab microwell enzyme immunoassay (bioMerieux, 
Marcy 1'Etoile, France). CD4 counts were determined 
using flow-cytometry technique (Becton Dickinson Facs 
Count machine with BD Facscount™ reagent).
Data analysis was done by SPSS version 10-software for 
Windows. Normally distributed values were presented as 
mean plus standard deviation (SD). In other cases data 
were expressed as mean plus standard error mean (SEM). 
Chi-square was used to express correlations between 
dichotomous variables and Spearman's correlation coeffi­
cient, to quantify correlations between continuous varia­
bles. P-value equal to or less than 0.05 was regarded as 
statistically significant.
Ethical clearance was obtained from the Research Ethics 
Committee of KCMC hospital and a signed informed writ­
ten consent was obtained from patients prior to enrol­
m ent of the patients in the study.
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